Design of new synthetic methodologies
- Design, synthesis and biological evaluation of new inhibitors of GPCR, TK and RTK (cancer), HIV (AIDS), HCV (Hepatitis C) and Myotonic Dystrophy.
- Design of new synthetic methodologies for heterocyclic systems based on microwaves.
MEMBER OF:
School of Engineering
Pharmaceutical Chemistry Group
The research focuses on two main areas: New Drugs in Biomedicine and Health Sciences and Flow Chemistry Processes.
LATEST PROJECTS
DisX4lymph (Interrupción de la interacción estroma-tumor en linfoma B utilizando inhibidores CXCR4 y degradadores IRAK4)
Diseño y síntesis de inhibidores alostéricos de CXCR4 y degradadores de IRAK4 como potencial tratamiento de linfoma de células B.
Funding Agency:
Research Group Link:
Pharmaceutical Chemistry Group (GQF)
PreClinIQS080 (Estudio Preclínico Inicial de IQS080, un candidato a fármaco contra el cáncer de páncreas)
Estudio Preclínico de un potente inhibidor multidiana in vitro dirigido a tirosina quinasas intracelulares implicadas en el cáncer de páncreas
Funding Agency:
Research Group Link:
Pharmaceutical Chemistry Group (GQF)
MNK inhibitor (Overcoming therapy resistance and immune evasion with a novel MNK inhibitor)
Development of a novel MNK inhibitor to treat breast and prostate cancer
Funding Agency:
Research Group Link:
Pharmaceutical Chemistry Group (GQF)
LINKED NEWS
Research
New Tyrosine Kinase Inhibitors Against Lymphoma
09/05/2023
Researchers from the IQS Pharmaceutical Chemistry Group and the Josep Carreras Leukaemia Research Institute are collaborating on the DisX4lymph project to look for new agents for the treatment of aggressive B-cell lymphoma.
READ FULL NEW
Doctoral thesis
TKI inhibitors for lypmhoma therapies
31/03/2023
Dr Victor Masip recently defended his doctoral thesis at IQS, in which he designed, synthesized, and characterized potential new inhibitors of the ZAP-70 protein for peripheral T lymphoma therapies.
READ FULL NEW
News
New Therapies to Treat Leukaemia
08/07/2022
IQS has participated in the European project PROTEOblood, a cross-border project with the aim of studying and seeking new leukaemia and lymphoma treatments through understanding protein degradation and destruction cycles.
READ FULL NEW
News
Pharmacokinetic and Efficacy Studies
27/07/2021
IQS and the company Xenopat recently signed a collaboration agreement to carry out joint research projects concerning cancer and offer services to third parties by combining both entities' experience, including ADME-Tox, computational prediction, and in vivo efficacy studies, among other pharmacokinetic studies.
READ FULL NEW
